omniture
logo
Search
云顶新耀医药科技有限公司
Media Room

Latest News

rss

Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-11-19 07:40 1402

Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients

SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2024-10-25 07:40 1623

Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine

SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-10-22 07:40 1732

Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy

SHANGHAI , Oct. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2024-10-21 07:40 1697

Everest Medicines Announces Interim Results for First Half of 2024

SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-08-28 08:00 2186

Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16

SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-08-22 08:00 1964

Everest Medicines to Announce 2024 Interim Results on August 28, 2024

SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2024-08-06 07:30 2905

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-07-22 09:00 1935

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-07-18 08:00 2032

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2024-07-15 13:44 1851

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2024-05-14 21:41 2356

Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

SHANGHAI, May 8, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")...

2024-05-08 08:05 2170

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

SHANGHAI, May 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")...

2024-05-02 09:23 2763